Bachar Samra, MD

Bachar Samra, MD, is a triple board-certified hematologist and oncologist at Kelsey-Seybold. After completing his medical degree at Saint Joseph University in Beirut, Lebanon, in 2012, he relocated to New York, where he completed both an internship and Internal Medicine residency at Northwell Health Staten Island University Hospital in 2014 and 2016, respectively. Dr. Samra also completed a fellowship in Hematology/Oncology at SUNY Downstate Medical Center in Brooklyn, New York, in 2019 where he also served as Chief Fellow. Then he pursued Leukemia fellowship at MD Anderson Cancer Center . He joined Kelsey-Seybold in January 2025.

Dr. Samra’s passion for patient care inspires him to pursue the cutting edge of the scientific revolution in Oncology and Hematology. He provides care in all aspects of benign and malignant blood disorders and cancer, with a particular interest in hematologic malignancies, lung cancer, and community oncology. Dr. Samra’s favorite aspects of practicing medicine are the opportunities to build human connections and help people improve their health, especially in difficult times.

Dr. Samra believes that showing respect, establishing a good rapport, and getting to know the patient well as a whole are vital to building a trusting patient-physician relationship. He strives to be upfront and honest from day one, listening and communicating well to set expectations and goals and empower his patients with the understanding and knowledge they need to participate in their own care decisions. Dr. Samra also aspires to provide high-quality evidence-based medicine compassionately every day.

Outside of caring for patients, Dr. Samra enjoys sports, reading, music, family time, dining out, and traveling.

Awards & Publications

Awards

• American Society of Hematology 2019 Abstract Achievement Award
• NCI Community Oncology Research Program Silver Certificate of Excellence for exceptional achievement in patient enrollments in National Cancer Institute treatment and cancer control trials, 2024

Publications

Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, & Jabbour E. Long term outcome of Hyper-CVAD for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapses. Blood Advances. 2021 October. PMID 34464974

Assi T, Watson S, Samra B, Rassy E, Le Cesna E, Italiano A, & Mir O. Targeting the VEGF pathway in osteosarcoma. Cells. 2021 May. PMID 34069999

Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, & Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 April. PMID 33793964

Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, & Daver N. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021 March. PMID 33681815

Samra B, Konopleva M, Isidori A, Daver N, & DiNardo CD. Venetoclax-based combinations in acute myeloid leukemia: Current evidence and future directions. Front Oncol. 2020 November. PMID 33251134

Samra B, Kantarjian H, Sasaki K, Alotaibi AS, O’Brien S, Ferrajoli A, Garris R, Konopleva M, Nunez C, Kadia T, Short NJ, & Jabbour E. Discontinuation of maintenance tyrosine kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia outside of transplant. Acta Haematol. 2020 August. PMID 33238261

Shoukier M, Kadia TM, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, & Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 February. PMID 33119202

Rassy E, Khoury-Abboud R, Ibrahim N, Assi T, Samra B, Hanna C, El karak F, & Ghosn M. Should we screen patients with hematologic malignancies for COVID-19? Hematol Oncol. 2020 July. PMID 32779823

Assi T, Samra B, Dercle L, Rassy E, Kattan J, Ghosn M, Houot R, & Ammari S. Screening strategies for COVID-19 in patients with hematologic malignancies. Front Oncol. 2020 July. PMID 32719749

Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, & Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 June. PMID 32501545

Samra B, Jabbour E, Ravandi F, Kantarjian H, & Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: State-of-the art treatment and future directions. J Hematol Oncol. 2020 June. PMID 32503572

Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, & Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2021 September. PMID 32501545

Samra B, Richard-Carpentier G, Kadia T, Ravandi F, Daver N, DiNardo CD, Issa G, Bose P, Konopleva M, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, & Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 May. PMID 32366832

Chiu E, Samra B, Tam E, Baseri B, Luhrs C, Gonsky G, Sawas A, Taiwo E, & Sidhu G. Clinical characteristics and outcomes of Caribbean patients with adult T-cell leukemia/lymphoma at two affiliated New York City hospitals. JCO Glob Oncol. 2020 April. PMID 32243210

Mubarak G, Haddadin M, Samra B, Luhrs C, & Taiwo E. Doxorubicin-associated Takotsubo cardiomyopathy in a patient with Adult T-cell leukemia/lymphoma: Case report and review of the literature. Clin Case Rep. 2019 Nov. PMID 31893081

Baseri B, Samra B, Tam E, Chiu E, & Leaf A. An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Rep Oncol Med. 2019. PMID 31885970

Samra B, Ghanem S, Ilyas I, & Taiwo E. Screening colonoscopy unmasking colonic metastasis from an occult breast ductal carcinoma: Case report and review of the literature. Case Rep Oncol Med. 2019. PMID 30918733

Samra B, Tam E, Baseri B, & Shapira I. Immune checkpoint inhibitors in head and neck cancers: current knowledge and perspectives. J Investig Med. 2018 June. PMID 29941547

El Hage H, Hossri S, Samra B, & El-Sayegh D. Primary pulmonary Hodgkin’s lymphoma: a rare etiology of a cavitary lung mass. Cureus. 2017 August. PMID 29098130

Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B, & Atallah JP. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Review of Anticancer Therapy. 2016 November. PMID 27841044

Azzi J, Khoury L, Yacoub H, Samra B, & Friscia P. Paraspinal masses due to myeloid metaplasia. Journal of Blood Disorders and Therapy. 2016

Samra B & Abdul-Hay M. Chronic leukemia a disease to conquer: types and treatment. OMICS Publishing Group. 2015 October (Book Chapter).

Samra B, Yasmin M, Arnaout S, & Azzi J. Idiopathic Hemophagocytic lymphohistiocytosis during pregnancy treated with steroids: a case report and review of literature. Hematology Reports. 2015 September. PMID 26487936